DOCSLIB.ORG

Luteal Phase Support: Why, When and How

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Luteal Phase Support: Why, When and How Review Article Luteal Phase Support: Why, When and How Aruna Nigam Professor, Department of Obstetrics and Gynaecology, Hamdard Institute of Medical Sciences and Research, Jamia Hamdard, New Delhi, India To cite: Nigam A. Luteal Phase Support: Why, When and How. Pan Asian J Obs Gyn 2018;1(2):6-10. ABSTRACT Received on: Luteal phase support (LPS) is a known intervention for preventing the pregnancy loss. It is most commonly used in the artificial reproduction cycles. Most common agent used for the luteal phase support is progesterone. Current review discusses the reasons of luteal phase Accepted on: defects in stimulated and unstimulated cycles and also analyses the utility of various drugs in the treatment of the same. Source of Support: Nil Keywords: Corpus luteum, luteal phase support, progesterone, artificial reproduction cycle. Conflict of Interest:None IntroduCtIon Progesterone levels at conception have been found linearly associated with miscarriage, preterm birth, Luteal phase support (LPS)is a known intervention for intrauterine growth retardation, and eutrophic term preventing the pregnancy loss for last many decades birth.1 and is a common practice among obstetricians. This For the adequate secretion of progesterone, the is more evident in the field of infertility, recurrent corpus luteum requires continuous stimulation by pregnancy loss and preterm labour. This review has luteinizing hormone (LH)which has a pulsatile secretion been done with the intend of finding the evidences from the pituitary under the influence of HCG. Basically, and reasons use of various agents for luteal phase HCG is secreted from developing syncytio-trophoblasts support. Reviews, original articles, guidelines have been of placenta from week 2 of implantation. It also interacts searched in PUBMED from 1995-2018 using the key with L-HCG receptor of the ovary to maintain the corpus words ‘luteal phase support’,‘recurrent pregnancy loss’, luteumso that corpus luteum continues to secrete ‘progesterone’, ‘infertility’ and ‘threatened miscarriage’. the progesterone for the support of pregnancy in the To understand the concept of LPS, one must first trimester. Corpus luteal cells develop from the understand the physiology of the luteal phase follicular cells surrounding the ovarian follicle. These follicular cells are either theca cells or luteal cells. After normal physIology of luteal ovulation theca cells luteinize into small luteal cells phase and granulosa cells luteinize into large luteal cells. Both Natural menstrual cycle is divided into follicular phase these cells secrete progesterone but the small luteal cells (proliferative phase) and Luteal phase (secretory phase). synthesize androgens besides progesterone due to the Follicular phase starts from menstruation and ends lack of aromatase enzyme whereas large luteal cells with ovulation. Luteal phase extends from ovulation secrete estrogen and inhibin A besides progesterone. to the establishment of pregnancy or start of menses. The studies have shown that although the progesterone This phase is governed by corpus luteum which secretes is most important component for the luteal support progesterone and estradiol. If the patient conceives, but the estrogen should also be given importance as embryo implantation occurs on around 6th day. This evidenced by the studies1,2 where the better results have embryo implantation process is complicated and been obtained on stimulating the follicular phase only largely depends on the local environment supported to optimize the luteal phase producing higher estrogen by progesterone mainly and the human chorionic and progesterone. Estradiol metabolites from corpus gonadotropin (HCG) hormone secreted by the luteum may play role in angiogenesis and its lifespan developing blastocyst to maintain the corpus luteum. and regression.2 6 AIM Publications www.pajog.com Luteal Phase Support: Why, When and How It is important to remember that corpus luteum 3. GnRH agonist supplementation to prevent requires continuous LH stimulation for adequate spontaneous LH rise may also delay the pituitary steroidogenic activity (progesterone secretion) and in recovery to stimulate the corpus luteum. the event of LH withdrawal, premature luteolysis occurs. 4. Another reason of LPD in IVF cycles is the suppression It has been observed that if corpus luteum is removed of LH production in the final stages of oocyte prior to 7 weeks of gestation, it leads to pregnancy maturation because of HCG administaration loss. This pregnancy can be supported by high dose of 5. In the GnRH antagonist treated IVF cycles, premature progesterone supplementation. luteolysis causes LPD and decreases the chances of pregnacncy. luteal phase defeCt (lpd) In ARTcycles, depending upon the type of stimulation, Any problems with the progesterone secretion during LPD can be of 4 types the secretary phase leads to defective luteal phase • Luteal phase of monofollicular cycle: There is which is clinically observed by the early menses in a less impairment of luteal phase because of milder stimulated cycle. LPD is usually observed in cases of stimulation. polycystic ovarian disease, recurrent pregnancy loss • Luteal phase after controlled ovarian and stimulated/invitro fertilization (IVF) cycles. LPD hyperstimulation (COH) in which GnRHanalogs has also been observed around 8% of normo-ovulatory have been used:Intense ovarian stimulation patients who present with infertility.3 protocols need high progesterone support for It is said the half of the LPD occurs due to the defect reasons discussed above. in gonadotropin releasing hormone (GnRH) pulse • Luteal phase where GnRH antagonists have been generation. With the more understanding of the corpus used with GnRh agonist used as trigger leading to luteum function the subclassification of the LPD of premature luteolysis: Here stimulation is intense ovarian origin has given according to the dysfunction stimulation intense but lesser than above and needs of small/large luteal cells.4 As the small luteal cells are LP support. LH responsive, if there is improper development of • Artificial cycle where ovulation is suppressed and these cells, these cells will not secrete progesterone thawed embryo has been implanted: Due to the under the influence of normal LH pulses this is known absence of corpus luteum, endometrial receptivity as small luteal cell defect. Large cell luteal defect is totally dependent on exogenously supported results in decrease in basal level of progesterone levels sex steroids. These cycles have also helped us to in presence of normally secreted progesterone under understand the efficacy of different luteal phase the influence of LH.This subclassification is important support preparations, doses, regimens, and routes as the treatment varies in different defects. In case of administration.8 of LH responsive large cells corpus luteum defect HCG and GnrRH pulses will be beneficial but in case treatment for luteal phase of LH unresponsive small cell defect, progesterone defeCt supplementation is needed. Progesterone is the main stay of the treatment but It is well proven that IVF cycles are almost always there is still controversy regarding the type and associated with LPD because of varied reason as route of progesterone preparations. Most common discussed below5:6 progesterone used is micronized progesterone followed 1. It is said that the removal large amount of granulosa by dydogesterone. Former can be given by various cells during oocyte retrieval diminishes the source routes but the latter can be used by oral route only. of progesterone. 2. Multifollicular development in the IVF cycle leads to Supraphysiological levels of steroids due to high role of progesterone number of corpora lutea. This directly inhibits the Besides maintenance of pregnancy, LH release via pituitary through negative feedback 1. It also improves the endometrial receptivity in leading to LPD.7 adequately estrogenized endometrium. Pan Asian Journal of Obstetrics & Gynecology, September-December 2018;1(2):6-10 7 Aruna Nigam 2. It stabilizes lysosomal membranes leading to Natural micronized progesterone (NMP)14,15: The quiescent uterus. problem of lesser bioavailability have been overcome by 3. It blocks the chemokines - transcription factor, NF- the invent of sustained released preparations of the NMP KB leading to inhibition of prostaglandin synthesis in last decade. This preparation is provided in a methyl- causing uterine relaxation. This is also supported by cellulose base which hydrates in the gastrointestinal the reduced intracellular calcium concentration and tract causing a slow release of progesterone. Oral NMP lowered amount of phosphorylated myosin. have high protein binding with long half-life (18 hours) 4. It causes uterine relaxation by causing nitric oxide leading to once a dosage benefit. The ‘Smooth’ release synthesis. pattern of the drug helps in maintenance of the steady 5. It increases endometrial vascularity and promotes drug levels in blood because of decreased hepatic secretory transformation of endometrium. metabolism. 6. Progesterone along with HCG and cortisol inhibits Both dydrogesterone and NMP are associated with the tissue rejection and protect the conceptus by its similar rates of successful pregnancies (24.1% versus immunomodulatory action. 22.8% respectively).16,17 7. Progesterone positively regulates‘Progesterone Induced Blocking Factor’, ‘Natural Killer cells’, HOX- Vaginal preparations of the progesterones 10, trophoblast HLA gene leading
Load more

Recommended publications
  • Luteal Phase Defect (LPD): a Necessary Tool in Assisted Reproductive Techniques
    Indian Journal of Obstetrics and Gynecology Research 2021;8(1):1–9 Content available at: https://www.ipinnovative.com/open-access-journals Indian Journal of Obstetrics and Gynecology Research Journal homepage: www.ijogr.org Review Article Luteal Phase Defect (LPD): A necessary tool in assisted reproductive techniques P R Pant1,*, Uma Shrivastava2, Sabina Simkhada2, Swasti Sharma3, Chetna Shrestha4, Usha Shrestha5, Tumla Lacoul6 1Dept. of Obstetrics and Gynecology, Grande Hospital, Kathamandu, Nepal 2Infertility & IVF Centre 3 Infertility Care Center at Greencity Hospital, Kahtmandu, Nepal 4Greencity IVF, Kahtmandu, Nepal 5Paropakar Maternity & Women’s Hospital, Kathmandu, Nepal 6Sukhi Pariwar Clinic, Kahtmandu, Nepal ARTICLEINFO ABSTRACT Article history: In Luteal Phase Defect (LPD), endogenous progesterone is insufficient to maintain a functional secretory Received 31-10-2020 endometrium and also inhibit embryo growth and implant. In 1960, it was estimated that 20 million Accepted 10-11-2020 pregnancies were exposed to Dydrogesterone in utero. LOTUS I and LOTUS II two major multicenter Available online 13-03-2021 Phase III studies were conducted on patients who were planning to undergo In Vitro Fertilization (IVF) with or without Intracytoplasmic Sperm Injection (ICSI). The result of both studies shows that Dydrogesterone was non-inferior to micronized vaginal progesterone, which was the presence of fetal heartbeats at 12 weeks Keywords: of gestation. Progesterone which can be administered either by oral preparation, vaginal administration LPD along with optimal use of estrogen and Gonadotropin-Releasing Hormon (GnRH) agonist drugs is used in LOTUS the treatment of LPD. Studies have suggested the use of Dydrogesterone in fresh IVF cycles and Luteal Progesterone Phase Support (LPS) is continued till 10–12 weeks.
    [Show full text]
  • Luteal Phase Support Using Oral Dydrogesterone-A Prospective Treatment for Future Replacing Micronized Vaginal Progesterone
    Open Access Journal of Reproductive System and L UPINE PUBLISHERS Sexual Disorders Open Access DOI: 10.32474/OAJRSD.2018.01.000119 ISSN: 2641-1644 Review article Luteal Phase Support using Oral Dydrogesterone-a Prospective Treatment for Future Replacing Micronized Vaginal Progesterone Kulvinder Kochar Kaur1*, Gautam Allahbadia2 and Mandeep Singh3 1Scientific Director, Centre For Human Reproduction, Punjab, India 2Department of Obstetrics and Gynecology, Mumbai, India 3Department of Neurology, Swami Satyanand Hospital, Punjab, India Received: September 03, 2018; Published: September 10, 2018 *Corresponding author: Jalandhar-144001, Punjab, India Kulvinder Kochar Kaur, Scientific Director, Centre For Human Reproduction 721, G.T.B. Nagar, Abstract Although micronized vaginal progesterone is the accepted norm for use in luteal phase support (LPS) in controlled ovarian stimulation (COS) that is used for in vitro fertilization (IVF) cycles, recently importance of oral Dydrogesterone has got the overimportance micronized in lieu vaginal of its progesteroneoral availability, and cheap, it seems no Dcumbersome might soon sidebecome effects the andstandard no definitive of care fornewer LPS fetalin conventional side effects. IVF After cycles the besidesLOTUS 1 its trial routine with indicationa multicenter for recurrentdouble placebo, abortions. double dummy design it has proved an equal efficacy if not superiority of oral D, Keywords: Abbreviations:LPS; COS; IVF; Dydrogesterone; Micronized vaginal progesterone LPS: Luteal Phase Support; COS: Controlled Ovarian Stimulation; IVF: In Vitro Fertilization; ET: Embryo Transfer Dydrogesterone(D)-Pharmacology growth along with corpus luteum formation and maintenance. A potent orally active progesterone receptor agonist D was humans [6], although in recent times 20mg/d of D got used as an Clinically used doses of 5-30mg, they do not suppress ovulation in developed in the1950’s.
    [Show full text]
  • Luteal Support with Very Low Daily Dose of Human Chorionic Gonadotropin After Fresh Embryo Transfer As an Alternative to Cycle S
    pharmaceuticals Article Luteal Support with very Low Daily Dose of Human Chorionic Gonadotropin after Fresh Embryo Transfer as an Alternative to Cycle Segmentation for High Responders Patients Undergoing Gonadotropin-Releasing Hormone Agonist-Triggered IVF Andrea Roberto Carosso 1,*,† , Stefano Canosa 1,† , Gianluca Gennarelli 1 , Marta Sestero 1, Bernadette Evangelisti 1, Lorena Charrier 2 , Loredana Bergandi 3 , Chiara Benedetto 1,‡ and Alberto Revelli 1,‡ 1 Obstetrics and Gynecology 1U, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, Sant’Anna Hospital, University of Torino, 10042 Turin, Italy; [email protected] (S.C.); [email protected] (G.G.); [email protected] (M.S.); [email protected] (B.E.); [email protected] (C.B.); [email protected] (A.R.) 2 Department of Public Health and Pediatrics, University of Torino, Via Santena, 5 bis, 10126 Torino, Italy; [email protected] 3 Department of Oncology, University of Torino, Via Santena 5 bis, 10126 Torino, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-333-8111155 or +39-011-3135763 † These authors contributed equally to this work. Citation: Carosso, A.R.; Canosa, S.; ‡ These authors jointly supervised this work. Gennarelli, G.; Sestero, M.; Evangelisti, B.; Charrier, L.; Bergandi, Abstract: The segmentation of the in vitro fertilization (IVF) cycle, consisting of the freezing of L.; Benedetto, C.; Revelli, A. Luteal all embryos and the postponement of embryo transfer (ET), has become popular in recent years, Support with very Low Daily Dose of Human Chorionic Gonadotropin after with the main purpose of preventing ovarian hyperstimulation syndrome (OHSS) in patients with Fresh Embryo Transfer as an high response to controlled ovarian stimulation (COS).
    [Show full text]
  • Progestin - Wikipedia, the Free Encyclopedia
    Progestin - Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/Progestin From Wikipedia, the free encyclopedia A progestin is a synthetic[1] progestogen that has progestinic effects similar to progesterone. [2] The two most common uses of progestins are for hormonal contraception (either alone or with an estrogen), and to prevent endometrial hyperplasia from unopposed estrogen in hormone replacement therapy. Progestins are also used to treat secondary amenorrhea, dysfunctional uterine bleeding and endometriosis, and as palliative treatment of endometrial cancer, renal cell carcinoma, breast cancer, and prostate cancer. High-dose megestrol acetate is used to treat anorexia, cachexia, and AIDS-related wasting. Progesterone (or sometimes the progestin dydrogesterone or 17α-hydroxyprogesterone caproate) is used for luteal support in IVF protocols, questionably for treatment of recurrent pregnancy loss, and for prevention of preterm birth in pregnant women with a history of at least one spontaneous preterm birth.[3] They are also used in judicial chemical castration of sex offenders as well as a treatment options for those suffering from paraphilia. Co-inventor Luis E. Miramontes's signed laboratory notebook. October 15, 1951 1 History 2 Examples 3 Methods of progestin-based contraception 4 See also 5 References The recognition of progesterone's ability to suppress ovulation during pregnancy spawned a search for a similar hormone that could bypass the problems associated with administering progesterone (low bioavailability when administered
    [Show full text]
  • The Inadequate Corpus Luteum
    ID: XX-XXXX; -20-0044 2 1 W C Duncan Inadequate corpus luteum 2:1 C1–C7 COMMENTARY The inadequate corpus luteum W Colin Duncan MRC Centre for Reproductive Health, The University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, UK Correspondence should be addressed to W C Duncan: [email protected] Abstract The corpus luteum is the source of progesterone in the luteal phase of the cycle and the initial two-thirds of the first trimester of pregnancy. Normal luteal function is required for fertility and the maintenance of pregnancy. Progesterone administration is increasingly used during fertility treatments and in early pregnancy to mitigate potentially inadequate corpus luteum function. This commentary considers the concept of the inadequate corpus luteum and the role and effects of exogenous progesterone. Progesterone supplementation does have important beneficial effects but we should be wary of therapeutic administration beyond or outside the evidence base. Lay summary After an egg is released a structure is formed on the ovary called a corpus luteum (CL). This produces a huge amount of a hormone called progesterone. Progesterone makes the womb ready for pregnancy but if a pregnancy does not happen the CL disappears after 12–14 days and this causes a period. If a pregnancy occurs, then the pregnancy hormone (hCG) keeps the CL alive and its progesterone supports the pregnancy for the next 6–8 weeks until the placenta takes over and the corpus luteum disappears. That means that if the CL is not working correctly there could be problems getting pregnant or staying pregnant.
    [Show full text]
  • Cukurova Medical Journal Micronised Vaginal Progesterone Versus Oral
    Cukurova Medical Journal Cukurova Med J 2021;46(1):32-38 ÇUKUROVA ÜNİVERSİTESİ TIP FAKÜLTESİ DOI: 10.17826/cumj.783436 ARAŞTIRMA / RESEARCH Micronised vaginal progesterone versus oral dydrogestrone in the treatment of dysfunctional uterine bleeding: efficacy and effects on lipid profile Disfonksiyonel uterin kanamanın tedavisinde mikronize vajinal progesteron ile oral didrogestronun karşılaştırılması: etkinlikleri ve lipid profili üzerindeki etkileri Abdullah Tok1 , Gülcan Akdemir1 , Alev Özer1 , Gürkan Kıran1 1Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi, Kadın Hastalıkları ve Doğum Anabilim Dalı, Kahramanmaraş, Turkey Cukurova Medical Journal 2021;46(1):32-38 Abstract Öz Purpose: The aim of this study was to compare the Amaç: Bu çalışmanın amacı, kısa süreli oral didrogesteron efficacy of short-course oral dydrogesterone versus vaginal ile vajinal mikronize progesteronun etkinliğini micronized progesterone and to determine their effects on karşılaştırmayı ve disfonksiyonel uterin kanamalı the lipid profile of the premenopausal women with premenopozal kadınlarda lipid profili üzerindeki etkilerini dysfunctional uterine bleeding. belirlemeyi amaçlamaktadır. Materials and Methods: A total of 70 premenopausal Gereç ve Yöntem: Disfonksiyonel uterin kanaması olan women with dysfunctional uterine bleeding were randomly toplam 70 premenopozal kadın, çalışmaya dahil edildi. 35 assigned to receive 90 mg of vaginal micronized hastaya (Grup 1) 90 mg vajinal mikronize progesteron (% progesterone (8% gel) (Group 1, n = 35) or 20 mg of oral 8 jel), diğer 35 hastaya20 mg oral didrogesteron (Grup 2) dydrogesterone (Group 2, n = 35). The group 1 treatment almak üzere rastgele atandı. Grup 1 tedavisi, adet consisted of self-application of vaginal progesterone, every döngüsünün 17. ila 27. günü arasında her akşam üç döngü other evening from the 17th to the 27th day of the boyunca kendi kendine vajinal progesteron menstrual cycle, for three cycles.
    [Show full text]
  • Individualized Luteal Phase Support
    CE: Alpana; GCO/310301; Total nos of Pages: 6; GCO 310301 REVIEW CURRENT OPINION Individualized luteal phase support Barbara Lawrenza,b, Carol Coughlanc, and Human M. Fatemia Purpose of review The aim of this review is to summarize the different aspects of luteal phase deficiency in IVF treatment and the possibilities of individualized luteal phase support. Recent findings 03/26/2019 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3iopPs8eUYypm2mXpsqYu+FTQQCfFlSo+95KUwgaSqwb665CtKO6gUQ== by https://journals.lww.com/co-obgyn from Downloaded Downloaded After the application of human chorionic gonadotrophin (hCG) for final oocyte maturation, the vaginal route for progesterone administration is sufficient to maintain an adequate luteal phase support. New data point toward the possibility of oral medication; however, those data have yet to be confirmed in larger from https://journals.lww.com/co-obgyn studies. Luteolysis after gonadotropinrealzing hormone (GnRH) agonist trigger is patient specific and not always severe. According to the progesterone level, individualized low dosages of hCG can be applied as luteal phase support without the risk of ovarian hyperstimulation syndrome (OHSS) development. Summary It is the task of the reproductive medicine specialist to individualize luteal phase support according to the by patient’s specific characteristics, needs and desires and the type of treatment performed. The greatest BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3iopPs8eUYypm2mXpsqYu+FTQQCfFlSo+95KUwgaSqwb665CtKO6gUQ==
    [Show full text]
  • Pharmacokinetics of Hard Micronized Progesterone Capsules Via Vaginal
    Drug Design, Development and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study This article was published in the following Dove Press journal: Drug Design, Development and Therapy Hanbi Wang,1 Meizhi Liu,1 Purpose: This study aimed to evaluate the pharmacokinetics of hard micronized progester- Qiang Fu,2 Chengyan Deng1 one capsules (Yimaxin) via the vaginal or oral route compared with soft micronized progesterone capsules (Utrogestan) in a Chinese population. 1Reproductive Center, Department of Obstetrics and Gynecology, Peking Union Methods: A prospective single-center randomized open-label trial was conducted in 16 healthy Medical College Hospital, Chinese postmenopausal women. They were randomized into two groups to receive four phases of treat- Academy of Medical Sciences, Beijing, ment: vaginal Yimaxin, vaginal Utrogestan, oral Yimaxin, or oral Utrogestan, with different People’s Republic of China; 2Department of Pharmacy, Peking Union Medical sequences. College Hospital, Chinese Academy of Results: By the vaginal route, steady-state maximum concentration (Cmax) of Yimaxin and Medical Sciences, Beijing, People’s Republic of China Utrogestan was 29.13±8.09 and 12.30±1.60 mg/L, time to Cmax 9.72±10.50 and 11.03±9.62 hours, central compartment volume of distribution 4.26±1.86 and 10.40±2.32 L, clearance rate 0.18±0.05 and 0.38±0.10 L/h, and AUC 261.42±74.36 and 116.83±19.72 h·ng/mL, respectively.
    [Show full text]
  • Luteal Progesterone Level Correlated with Immunotherapy Success of Patients with Repeated Implantation Failures
    bioRxiv preprint doi: https://doi.org/10.1101/603720; this version posted April 9, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Luteal progesterone level correlated with immunotherapy success of patients with repeated implantation failures Omar Sefrioui1Y, Aicha Madkour2*Y, Nouzha Bouamoud2, Ismail Kaarouch1,2,3, Brahim Saadani4, Saa¨ıdAmzazi2, Henri Copin5, Moncef Benkhalifa5, Noureddine Louanjli3, with the Lorem Ipsum Consortium 1 Anfa Fertility center, Private Clinic of Human reproduction and endoscopic surgery, Casablanca, Morocco 2 Biochemistry and Immunology Laboratory, Mohammed V University in Rabat, Faculty of Sciences, Rabat, Morocco 3 Labomac IVF centers and clinical laboratory medicine, Casablanca, Morocco 4 IVF center IRIFIV, Clinique des Iris, Casablanca, Morocco. 5 Reproductive Biology and Medical Cytogenetics Laboratory, Regional University Hospital and School of Medicine, Picardie University Jules Verne, Amiens, France YThese authors contributed equally to this work. [email protected] Abstract Immunotherapy using PBMC administration demonstrated relatively its effectiveness to treat RIF patients but it still unclear to explain some miscarriages. Luteal progesterone level (LPL) issued from corpus luteum after embryo implantation stage could be informative basis data to personalize immunotherapy for RIF patients predicting clinical outcomes. This randomized controlled study included 70 patients undergoing ICSI program presenting at least 3 RIF: 39 for Control of untreated patients and 31 for PBMC-test concerning treated patients with immunotherapy. For PBMC-test group, Peripheral Blood Mononuclear Cells (PBMCs) were isolated from patients on ovulation induction day and cultured three days to be administered to intrauterine cavity of patients two days before fresh embryo transfer.
    [Show full text]
  • Progesterone in Assisted Reproduction: Classification, Pharmacology and Its Clinical Coorelation: a Commentary
    Scient Women’s Health & Gynecology Open Access Exploring the World of Science ISSN: 2369-307X Research Article Progesterone in Assisted Reproduction: Classification, Pharmacology and Its Clinical Coorelation: A Commentary This article was published in the following Scient Open Access Journal: Women’s Health & Gynecology Received January 22, 2020; Accepted January 31, 2020; Published February 06, 2020 Rathod K1*, Purohit P2, Kunde K3 and Narvekar N4 Abstract 1Consultant in Obstetrics and Gynaecology Whipps The modulating effects of progesterone on endometrium structure and function are the Cross Hospital, London UK basis for successful outcome in reproductive treatments. Considering this, progesterone 2Consultant in Obstetrics and Gynaecology Princess has a big role in treatment of infertility and supporting the ongoing pregnancy. In this review Royal University Hospital, London UK article we have attempted to review different forms of progesterone, their metabolism 3Consultant Obstetrics and Gynaecologist, Guys and in the body and the role played by exogenous as well as endogenous progesterone in St Thomas’ Hospital, London UK assisted reproductive technologies (ART). Elevated serum progesterone levels at the end 4Consultant and Sub-specialist in Assisted of the follicular phase in controlled ovarian stimulation (COS) leads to a poorer ongoing Reproduction Kings College Hospital, London UK pregnancy rate in IVF cycles due to reduced endometrial receptivity. Keywords: Progesterone, luteal phase support (LPS), in-vitro fertilization (IVF), Ovarian hyperstimulation (OHSS), Controlled ovarian stimulation (COS), Artificial reproductive technology (ART). Learning objectives Progesterone • • Mechanism of action of Progesterone • Classification of progesterone • Pharmacokinetics and dynamics of progesterone • Preparation of progesterone’s • Potential advantages of progesterone in assisted reproduction •IntroductionCons of elevelated serum progesterone levels in ART It is a natural hormone (C-21 steroid) produced mainly by the theca lutein cells of the corpus luteum.
    [Show full text]
  • Is There Any Correlation Between Estradiol Supplementation, As Luteal Phase Support, and Clinical Pregnancy in ART Cycles?
    International Journal of Reproductive BioMedicine Volume 18, Issue no. 11, https://doi.org/10.18502/ijrm.v13i11.7964 Production and Hosting by Knowledge E Research Article Is there any correlation between Estradiol supplementation, as luteal phase support, and clinical pregnancy in ART cycles? A cross-sectional study Maryam Eftekhar1 M.D., Banafsheh Mohammadi1 M.D., Esmat Mangoli2 Ph.D., Maryam Mortazavi1, 3 M.D. 1Department of Obstetrics and Gynecology, Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 2Department of Reproductive Biology, Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 3Department of Gynecology and Obstetrics, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. Banafsheh Mohammadi and Esmat Mangoli are both Abstract corresponding authors. Background: Endometrial receptivity is one of the important factors in assisted Corresponding Author: reproductive technology (ART) success. In the luteal phase of an ART cycle, serum Banafsheh Mohammadi; estradiol (E2) and progesterone are often placed in low levels. Supporting the luteal Research and Clinical Center for Infertility, Bouali Ave., phase with progesterone is a usual method. Safayieh, Yazd, Iran. Objective: To evaluate the effects of E2 supplementation plus progesterone on the Postal Code: 8916877391 luteal phase support in the antagonist protocol who have undergone intracytoplasmic Tel: (+98) 3538247085 Email: sperm injection-embryo transfer cycles. [email protected] Materials and Methods: In this cross-sectional study, 200 patients with antagonist Esmat Mangoli; Research and stimulation protocol, who had undergone intracytoplasmic sperm injection treatment, Clinical Center for Infertility, Bouali Ave., Safayieh, Yazd, were divided into two groups based on the use of E2 supplementation.
    [Show full text]
  • Timing Luteal Support in Assisted Reproductive Technology: a Systematic Review
    Timing luteal support in assisted reproductive technology: a systematic review Matthew T. Connell, D.O.,a Jennifer M. Szatkowski, B.S.,a Nancy Terry,b Alan H. DeCherney, M.D.,a Anthony M. Propst, M.D.,c and Micah J. Hill, D.O.a a Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health and b National Institutes of Health Library, Bethesda, Maryland; and c Texas Fertility Center, Austin, Texas Objective: To summarize the available published randomized controlled trial data regarding timing of P supplementation during the luteal phase of patients undergoing assisted reproductive technology (ART). Design: A systematic review. Setting: Not applicable. Patient(s): Undergoing IVF. Intervention(s): Different starting times of P for luteal support. Main Outcome Measure(s): Clinical pregnancy (PR) and live birth rates. Result(s): Five randomized controlled trials were identified that met inclusion criteria with a total of 872 patients. A planned meta- analysis was not performed because of a high degree of clinical heterogeneity with regard to the timing, dose, and route of P. Two studies compared P initiated before oocyte retrieval versus the day of oocyte retrieval and PRs were 5%–12% higher when starting P on the day of oocyte retrieval. One study compared starting P on day 6 after retrieval versus day 3, reporting a 16% decrease in pregnancy in the day 6 group. Trials comparing P start times on the day of oocyte retrieval versus 2 or 3 days after retrieval showed no significant differences in pregnancy.
    [Show full text]